Xilio Therapeutics Ratios (2020-2026) | XLO

Ratios Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter)
-631.27%-656.69%-806.90%-474.74%-178.19%-10.47%-86.68%-111.73%
EBIT Margin (Quarter)
-623.84%-652.32%-790.55%-472.73%-177.71%-10.12%-86.48%-111.57%
EBITDA Margin (Quarter)
-623.84%-652.32%-790.55%-472.73%-177.71%-10.12%-86.48%-111.57%
Operating Margin (Quarter)
-623.84%-652.32%-790.55%-472.73%-177.71%-10.12%-86.48%-111.57%
Net Margin (Quarter)
-631.27%-656.69%-806.90%-474.74%-178.19%-10.47%-86.68%-111.73%
FCF Margin (Quarter)
846.54%-604.55%-821.52%979.04%-180.70%-91.76%-14.74%-181.05%
Efficiency
Assets Average (Quarter)
169.39M207.21M187.24M167.77M148.29M125.33M101.93M85.10M69.38M71.77M86.24M82.27M72.87M87.40M118.76M133.75M144.19M159.09M
Asset Utilization Ratio (Quarter)
0.110.130.240.300.34
Leverage & Solvency
Interest Coverage Ratio (Quarter)
-230.07-1.01-195.56-106.12-89.93-92.26-18.47-112.56-261.25-403.74-16.74-55.69-84.02-149.11-48.33-234.76-368.36-28.37-438.37-742.74
Debt Ratio (Quarter)
0.080.040.040.040.030.020.01
Times Interest Earned (Quarter)
-230.07-1.01-195.56-106.12-89.93-92.26-18.47-112.56-261.25-403.74-16.74-55.69-84.02-149.11-48.33-234.76-368.36-28.37-438.37-742.74
Valuation
Enterprise Value (Quarter)
-120.30M-99.77M-198.05M-176.96M-159.41M-139.14M-120.39M-93.27M-75.38M-59.77M-44.70M-33.98M-74.95M-61.26M-55.29M-89.07M-121.55M-103.76M-137.53M-150.30M
Return Ratios
Return on Sales (Quarter)
-0.06%-0.07%-0.08%-0.05%-0.02%0.00%-0.01%-0.01%
Return on Capital Employed (Quarter)
-47.92%-40.90%-47.97%-56.67%-70.10%-83.79%-101.61%-123.47%-148.11%-181.89%-142.19%-147.10%-132.84%-143.23%-86.42%-56.59%-47.75%-36.38%
Return on Assets (Quarter)
-0.01%0.00%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%0.00%0.00%0.00%0.00%